Drug intelligence / Profile preview

ampicillin + roxithromycin

Development stage: Preclinical
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Intravenous, Intramuscular

Overview

A combination antibiotic therapy consisting of ampicillin, a penicillin-type antibiotic that inhibits bacterial cell wall synthesis, and roxithromycin, a macrolide antibiotic that inhibits bacterial protein synthesis. This combination provides coverage against a broad spectrum of bacteria, including both typical and atypical pathogens that cause respiratory tract infections.

Targets

PBP (Penicillin-binding protein family)Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on ampicillin + roxithromycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ampicillin + roxithromycin.

Explore the full profile